《大行報告》瑞銀下調君實生物(01877.HK)目標價至77.7元 評級「買入」
瑞銀發表報告指,君實生物(01877.HK)今年上半年收入為21億元人民幣,按年上升268%,遜於該行預期。除了治療膀胱癌新藥「拓益」的銷售外,上半年收入亦包括美國生物製藥公司Coherus的1.5億美元前期付款,及禮來就中和抗體「Etesevimab」的里程碑付款等。
瑞銀下調君實生物股份目標價,由116.8元降至77.7元,評級維持「買入」,並調低「拓益」今年至2023年銷售預測,由15億元、20億元及26億元人民幣,降至10億元、13億元及20億元人民幣,以反映競爭劇烈。
該行同時調低集團相應年份盈利預測,其中今明兩年由原來預測每股盈利0.37元及0.46元人民幣,降至料虧損0.17元及0.19元人民幣。2023年每股盈利則由1.06元降至0.34元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.